Healthcare / Pharmaceutical RetailersTSXV
$0.51
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-171235.00 · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$89M
P/E
N/A
•EV/EBITDA
330.5x
↑ROE
-2.7%
↓Gross Margin
39.7%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.9M · net income $-1.4M · FCF $-171235.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.9M | $20.9M | $5.8M | — | — |
| Net Income | $-1.4M | $-1.4M | $-1.1M | $-470428.00 | $-517085.00 |
| EBITDA | $204073.00 | $204073.00 | $-835078.00 | $-470428.00 | $-563177.00 |
| EPS | — | — | -0.01 | -0.01 | -0.02 |
| Gross Margin | 39.7% | 39.7% | 37.7% | — | — |
| Operating Margin | -5.9% | -5.9% | -27.4% | — | — |
| Net Margin | -6.8% | -6.8% | -18.1% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.03 | — | — |
| Current Ratio | 5.14 | 5.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-171235.00 | $-171235.00 | $118078.00 | $-519458.00 | $-120183.00 |
| Returns | |||||
| ROE | -2.7% | -2.7% | -3.5% | -20.7% | -19.0% |
| Valuation | |||||
| EV/EBITDA | 330.48 | 330.48 | — | — | — |
| P/B | 1.71 | 1.71 | 1.27 | 3.72 | 3.59 |
| Growth & Yield | |||||
| Revenue Growth | 260.6% | 260.6% | — | — | — |
| EPS Growth | — | — | 0.0% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → n/d
Residual
+10.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.